Business
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at the 2025 Psychiatry Update ConferenceSAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.\n\n \n \n \n \n \n \n\n \n\"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition, including schizophrenia, schizoaffective disorder or mood disorder,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. \"The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of INGREZZA, at even the lowest dose.\"\nThe post-hoc analysis was conducted using data from 103 participants who reached the final Week 48 visit in the KINECT 4 clinical trial and assessed a proposed threshold for remission of tardive dyskinesia (TD) symptoms using the Abnormal Involuntary Movement Scale (AIMS). The threshold for remission was defined as an AIMS item score of ≤1 (rating of \"none\" or \"minimal\") in each of the seven body regions (items 1-7). The percentage who met the threshold for remission was analyzed by dose (40 mg and 80 mg) and by psychiatric diagnosis (schizophrenia or schizoaffective disorder, mood disorder).\nA majority of participants who received 48 weeks of once-daily INGREZZA reached the threshold for remission of TD while on treatment, regardless of underlying psychiatric diagnosis or dose:\n59.2% (61/103) of participants who completed the study achieved remission, including 58.6% (17/29) of participants on the 40 mg dose and 59.5% (44/74) of participants on the 80 mg dose.Both 40 mg and 80 mg doses of INGREZZA showed significant improvements in AIMS total scores, with mean baseline scores of 12.4 (40 mg) and 15.1 (80 mg) decreasing to 2.1 and 2.5, respectively, at Week 48.Remission rates were consistent across psychiatric diagnoses, with 57.7% (41/71) of participants with sch...